Development and In-Vitro Evaluation of Doxorubicin-Loaded Methacrylate Gelatin (GelMa)-Acrylamide Hydrogels for the Treatment of Malignant Pleural Mesothelioma

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2024 Dec 5

PMID 39633081

Authors

Nishant S Kulkarni

Gautam Chauhan

Mural Quadros

Dnyandev G Gadhave

Vivek Gupta

Affiliations

Soon will be listed here.

Abstract

Objective: Malignant pleural mesothelioma (MPM) is the most prevalent subtype of malignant mesothelioma that affects the pleural lining of the lungs. Conventionally, chemotherapy via systemic injections has shown limited efficacy due to off-target effects, and inefficacious deposition at the disease site. In our previous study, we reported the development and optimization of UV-initiated methacrylate gelatin (GelMa)-acrylamide based hydrogel formulation for local intracavitary administration of therapies. The current study utilizes a pre-established GelMa formulation for delivering a small molecule chemotherapeutic agent, Doxorubicin (Dox), against in-vitro MPM models.

Methods: Dox-loaded hydrogel (DLH) precursor solution was prepared by dissolving Dox in the precursor solution. The gels were characterized for physical properties such as gelling time, swelling index, bio adhesion, and injectability and were compared to blank hydrogels. Dox-loaded hydrogels were also tested for therapeutic efficacy in MPM cells in various 2D and 3D cell culture models.

Results: It was revealed that Dox-loaded hydrogels retained similar physical properties, including gelling time (< 25 s), swelling index (~ 1,200%), bio-adhesion (> 20 g detachment force), and injectability (< 2N force for injecting precursor), compared to blank hydrogels. Moreover, the gel formulation effectively sustained the release of hydrophilic Dox HCl over a period of 12 days by increasing the degree of crosslinking between GelMa and its crosslinkers. Further, the therapeutic efficacy of Dox was retained even after loading into hydrogels, indicating that no chemical interactions took place between gel excipients and the drug. Studies in MPM cell-based models revealed that DLH showed excellent potential in inhibiting 2D and 3D cell growth, with DLH being more effective than plain Dox in suppressing tumor growth in 3D spheroid models.

Conclusions: Overall, the results of the present study suggest that Dox-loaded hydrogels (DLH) may be a good candidate for efficacy study in preclinical mesothelioma models, with strong potential for clinical translation.

References

Frost G . The latency period of mesothelioma among a cohort of British asbestos workers (1978-2005). Br J Cancer. 2013; 109(7):1965-73. PMC: 3790169. DOI: 10.1038/bjc.2013.514. View

Reid A, de Klerk N, Magnani C, Ferrante D, Berry G, Musk A . Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis. Thorax. 2014; 69(9):843-50. DOI: 10.1136/thoraxjnl-2013-204161. View

Brims F . Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma. Cancers (Basel). 2021; 13(16). PMC: 8391310. DOI: 10.3390/cancers13164194. View

Sahu R, Ruhi S, Jeppu A, Al-Goshae H, Syed A, Nagdev S . Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies. Front Oncol. 2023; 13:1204722. PMC: 10353315. DOI: 10.3389/fonc.2023.1204722. View

Lippmann M, Cohen M, Chen L . Health effects of World Trade Center (WTC) Dust: An unprecedented disaster's inadequate risk management. Crit Rev Toxicol. 2015; 45(6):492-530. PMC: 4686342. DOI: 10.3109/10408444.2015.1044601. View

Kostron A, Friess M, Crameri O, Inci I, Schneiter D, Hillinger S . Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2015; 49(5):1516-23. DOI: 10.1093/ejcts/ezv398. View

Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P . Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14):2636-44. DOI: 10.1200/JCO.2003.11.136. View

Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272):375-386. DOI: 10.1016/S0140-6736(20)32714-8. View

Gautron Moura B, Gerard C, Testart N, Caikovski M, Wicky A, Aedo-Lopez V . Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. Cancers (Basel). 2023; 15(1). PMC: 9817856. DOI: 10.3390/cancers15010031. View

10.

Chemotherapy H, Report S, Szkorupa M, Klos D, Chudacek J, Hanuliak J . Hyperthermic intraoperative intrapleural chemotherapy and surgical cytoreduction as part of multimodal treatment of malignant pleural mesothelioma - case report M. Szkorupa1, D. Klos1, J. Chudacek1, J. Hanuliak1, M. Stasek1, O. Fischer2, R..... Rozhl Chir. 2020; 99(10):456-461. View

11.

Li J, Mooney D . Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2018; 1(12). PMC: 5898614. DOI: 10.1038/natrevmats.2016.71. View

12.

Vigata M, Meinert C, Pahoff S, Bock N, Hutmacher D . Gelatin Methacryloyl Hydrogels Control the Localized Delivery of Albumin-Bound Paclitaxel. Polymers (Basel). 2020; 12(2). PMC: 7077643. DOI: 10.3390/polym12020501. View

13.

Yue K, Trujillo-de Santiago G, Alvarez M, Tamayol A, Annabi N, Khademhosseini A . Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) hydrogels. Biomaterials. 2015; 73:254-71. PMC: 4610009. DOI: 10.1016/j.biomaterials.2015.08.045. View

14.

Xu H, Casillas J, Krishnamoorthy S, Xu C . Effects of Irgacure 2959 and lithium phenyl-2,4,6-trimethylbenzoylphosphinate on cell viability, physical properties, and microstructure in 3D bioprinting of vascular-like constructs. Biomed Mater. 2020; 15(5):055021. DOI: 10.1088/1748-605X/ab954e. View

15.

Liu Y, Chan-Park M . A biomimetic hydrogel based on methacrylated dextran-graft-lysine and gelatin for 3D smooth muscle cell culture. Biomaterials. 2009; 31(6):1158-70. DOI: 10.1016/j.biomaterials.2009.10.040. View

16.

Hurewitz A, Zucker S, Mancuso P, Wu C, DiMassimo B, Lysik R . Human pleural effusions are rich in matrix metalloproteinases. Chest. 1992; 102(6):1808-14. DOI: 10.1378/chest.102.6.1808. View

17.

Barenholz Y . Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; 160(2):117-34. DOI: 10.1016/j.jconrel.2012.03.020. View

18.

Zidar B, PUGH R, Schiffer L, Raju R, Vaidya K, Bloom R . Treatment of six cases of mesothelioma with doxorubicin and cisplatin. Cancer. 1983; 52(10):1788-91. DOI: 10.1002/1097-0142(19831115)52:10<1788::aid-cncr2820521005>3.0.co;2-#. View

19.

Klotz L, Lindner M, Eichhorn M, Grutzner U, Koch I, Winter H . Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma. J Thorac Dis. 2019; 11(5):1963-1972. PMC: 6588772. DOI: 10.21037/jtd.2019.04.93. View

20.

Sugarbaker D, Gill R, Yeap B, Wolf A, Dasilva M, Baldini E . Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013; 145(4):955-963. DOI: 10.1016/j.jtcvs.2012.12.037. View